EN
Home/United States/Blog/Weight-loss plateau on Zepbound or Wegovy: why does it happen, and what can change?
USUnited States Living with it

Weight-loss plateau on Zepbound or Wegovy: why does it happen, and what can change?

When weight stopped falling in the big trials, why the body pushes back, what the US labels say about the dose, and what else a prescriber may look at.

GLP Guidebook teamPublished Oct 14, 202610 min read17 sourcesWritten from published sources
What we checked17 sources, each one opened and linked to the sentence it supportsLast checked Oct 14, 2026 · Next review due Oct 14, 2027 · How we write

Written for the United States. Other country versions are coming.

The short answer

A plateau is expected. In a 2-year trial, weight loss on Wegovy 2.4 mg flattened out after about week 60. In one analysis, most people on Zepbound 5, 10 or 15 mg had reached a plateau by week 72. As weight falls, appetite pushes back. The US labels let a prescriber review the dose, and NIH lists other changes they may consider.

Key takeaways

  • In the 2-year STEP 5 trial, weight loss on Wegovy 2.4 mg flattened out after about week 60 and then held steady to week 104.1
  • In an analysis of SURMOUNT-1 by mostly Eli Lilly researchers, about 88 to 90 in 100 people who lost at least 5% on Zepbound 5, 10 or 15 mg had reached a plateau by week 72.4
  • One weight-loss review estimates that for each kilogram (2.2 lb) lost, appetite rises by about 100 calories a day while the body burns only 20 to 30 fewer.5
  • The Wegovy label allows a dose of up to 7.2 mg; in its trial, weight fell 18.8% on 7.2 mg against 15.5% on 2.4 mg, with skin tingling in 22 in 100 against 6.6
  • NIH says that if you lose less than 5% after 12 weeks on the full dose, your clinician will probably advise stopping, which is different from a plateau after good weight loss.8
On this page
  1. What counts as a plateau?
  2. When do Wegovy and Zepbound plateaus happen in trials?
  3. Why does weight loss slow down?
  4. Can the dose go up?
  5. What else might a prescriber look at?
  6. Can a plateau affect your insurance coverage?
  7. What should you not do during a plateau?
  8. Questions people ask
  9. How we researched this

What counts as a plateau?

A plateau is when your weight stops falling for weeks at a time, even though you keep taking the medicine. It usually comes after a period of steady loss.1,5

Before you go further
  • GLP‑1 medicines are prescription-only in the US. Talk to your prescriber before changing your dose, stopping or switching.
  • Label facts here come from the current US prescribing information (the “label”) for each brand.
  • Trial numbers are averages from groups of people. They are not a promise about you.
  • Every risk of these medicines is in our side-effects guide.

Researchers need a firm rule, so they define it. In one Zepbound analysis, a plateau meant losing less than 5% of body weight over 12 weeks, and in every 12 weeks after that.4

A plateau is not the same as the medicine not working from the start. Two US rules cover that early check:

  • NIH guidance: after 12 weeks on the full dose, check for a 5% loss. If you haven’t lost that much, your clinician “will probably advise you to stop taking it.”8
  • Saxenda label: check weight 16 weeks after starting, and stop if you have not lost at least 4% of your starting weight.12

A worked example. For someone starting at 220 lb (100 kg), 5% is 11 lb (5 kg), by our arithmetic.

When do Wegovy and Zepbound plateaus happen in trials?

In the trials, most of the weight came off in the first months, then the line flattened. On Wegovy 2.4 mg that happened after about week 60; on Zepbound 5, 10 or 15 mg, most people reached a plateau by week 72.1,4

NIH puts it simply: “Most weight loss takes place within the first 6 months of starting the medication.”8

First, here is how these trials work:

  • People are split into groups at random.
  • One group gets the medicine; the other gets a dummy injection (placebo) that looks the same.
  • Both groups get the same advice on diet and activity.
  • The gap between the groups is what the medicine added.
STEP 5Semaglutide 2.4 mg (Wegovy), 2 years

304 adults with obesity, or overweight with a weight-related health problem, for 104 weeks. Novo Nordisk paid for the trial.1

Weight change after 104 weeks

Wegovy 2.4 mg−15.2%
Dummy injection−2.6%

Weight loss “plateaued after approximately week 60 and was maintained” to the end of the trial.1

The harm beside it: stomach and gut problems in 82 in 100 on Wegovy 2.4 mg, against 54 in 100 on the dummy injection. About 6 in 100 on Wegovy stopped because of side effects, against 5 in 100 on the dummy.1

SURMOUNT-1Tirzepatide (Zepbound), 72 weeks

2,539 adults with obesity, or overweight with a weight-related health problem, no diabetes. Eli Lilly paid for the trial.3

Weight change after 72 weeks

15 mg−20.9%
10 mg−19.5%
5 mg−15.0%
Dummy injection−3.1%

In a later analysis by mostly Lilly-employed authors, the middle point for reaching a plateau was 24 to 36 weeks, depending on starting BMI.4

The harm beside it: stomach side effects were the most common, mostly mild to moderate and mainly while the dose was going up. Side effects made 4 to 7 in 100 on Zepbound stop, against 3 in 100 on the dummy injection.3

These are two separate trials with different people, so their numbers can’t be compared with each other.

In the Zepbound analysis, people on 10 or 15 mg, younger people and women tended to reach their plateau later.4 By week 72, 88 to 90 in 100 had reached one.4

Averages hide a wide range. In STEP 1, 86 in 100 people on Wegovy 2.4 mg lost at least 5% of their weight by week 68, against 32 in 100 on a dummy injection. Half of those on Wegovy 2.4 mg lost 15% or more, against 5 in 100 on the dummy.2 Put the other way, about 14 in 100 on Wegovy lost less than 5%. Stomach side effects made about 5 in 100 on Wegovy stop, against fewer than 1 in 100 on the dummy.2

A worked example. For someone starting at 220 lb (100 kg), the STEP 5 average of 15.2% is about 33 lb (15 kg), by our arithmetic. The SURMOUNT-1 average on 15 mg, 20.9%, is about 46 lb (21 kg).

Why does weight loss slow down?

The body pushes back against weight loss. As weight falls, appetite rises and the body burns a little less, until the two balance at a new, lower weight.5

A 2018 review by an NIH scientist and a university obesity doctor describes this pattern for weight loss in general, not for GLP‑1 medicines in particular. It says weight loss “stalls after several months” across many kinds of treatment.5

  • Appetite rises: about 100 calories a day more for each kilogram (2.2 lb) lost, by the review’s estimate.5
  • Burning falls: about 20 to 30 calories a day less for each kilogram lost.5
  • Appetite matters more: the review says appetite changes “likely play a more important role than slowing metabolism.”5

A worked example. After losing 22 lb (10 kg), that is roughly 1,000 extra calories of appetite and 200 to 300 fewer burned. That is our arithmetic from the review’s estimates. These are model estimates, not measurements of you.

The review adds that this pull happens below conscious awareness. People often blame themselves, it says, when biology explains much of it.5

Other things can add to the pull. NIH lists some medicines that may cause weight gain:9

  • some medicines for epilepsy, depression or psychotic disorders
  • corticosteroids (steroids)
  • insulin and sulfonylureas for diabetes
  • some blood pressure medicines (beta-blockers, alpha-blockers, calcium channel blockers)
  • some antihistamines for allergies

NIH also links too little sleep to weight gain. It names health problems too, such as an underactive thyroid (hypothyroidism), polycystic ovary syndrome (PCOS) and Cushing’s syndrome.9

Can the dose go up?

Sometimes, within the label’s limits. Both labels tell the prescriber to weigh “treatment response and tolerability” when choosing the long-term (maintenance) dose.6,7

  • Wegovy injection: the maintenance dose for weight is 1.7 mg or 2.4 mg (recommended) once a week. After at least 4 weeks on 2.4 mg, it may go up to 7.2 mg (Wegovy HD) if more weight loss is “clinically indicated”.6
  • Zepbound: the maintenance dose is 5, 10 or 15 mg once a week. It can rise in 2.5 mg steps after at least 4 weeks on the current dose, up to 15 mg.7
STEP UP (label Study 8)Semaglutide 7.2 mg vs 2.4 mg (Wegovy)

1,407 adults with obesity, no diabetes, for 72 weeks. People were put on 7.2 mg, 2.4 mg or a dummy injection from the start, not after a plateau.6

Weight change after 72 weeks

Wegovy 7.2 mg−18.8%
Wegovy 2.4 mg−15.5%
Dummy injection−3.9%

The harm beside it: skin tingling or burning (dysesthesia) in 22 in 100 on 7.2 mg, against 6 in 100 on 2.4 mg and none on the dummy. Vomiting: 22, 16 and 6 in 100. These side-effect counts include a second trial in people with diabetes.6

Because people started on 7.2 mg in this trial, it does not show what happens when someone who has plateaued on 2.4 mg steps up. Our Wegovy HD post covers the higher dose in detail.

Higher doses also bring more stomach effects. On Zepbound 5, 10 or 15 mg, 25 to 29 in 100 people had nausea, against 8 in 100 on a dummy injection.7

Free toolQuestions to take to your prescriber

Builds a printable list for your appointment. No sign-up.

Open the question list

What else might a prescriber look at?

NIH lists several options a clinician may weigh when weight loss stops or falls short. A higher dose is only one of them.8

  • changing the treatment plan, or trying a different weight medicine
  • trying a different eating, activity or lifestyle program
  • changing other medicines that might be causing weight gain
  • a referral to a bariatric (weight-loss) surgeon

The American Diabetes Association’s 2026 standards say the same in their own words. They now ask clinicians to cut back weight-promoting medicines where they can, and to consider other medicines when treatment needs changing.10 Our post on switching from one GLP‑1 to another covers what the US labels say about that.

Protein and strength

A 2025 joint advisory from four US nutrition and obesity groups gives targets for people on GLP‑1 medicines:11

  • Protein: 80 to 120 g a day. Higher targets of 1.2 to 1.6 g per kilogram of body weight have been proposed during weight loss.11
  • Strength: strength training at least 3 times a week, plus at least 150 minutes of moderate activity, such as brisk walking.11

The same advisory says people with or at risk of kidney problems should be monitored. If that is you, ask before raising your protein.11 Our life on a GLP‑1 guide has the day-to-day detail.

Can a plateau affect your insurance coverage?

It can. Some plans that cover weight-loss medicines approve them for a few months at a time and ask for proof of weight loss to continue.13

One published 2026 health-plan policy, from a Rhode Island plan, shows how this can work. It approves 6 months at a time. To continue, it asks for:13

  • proof of at least 5% loss from your starting weight, and
  • either continued weight loss, or a BMI of 18.5 to 24.9, or
  • if weight has stopped falling and BMI is 25 or more, proof that you are taking part in a weight-management program. The policy allows this last route only once.

Other plans set their own rules, so check yours. Our prior authorization post explains the paperwork, and the insurance section covers the big drug-benefit managers.

What should you not do during a plateau?

Don’t change the dose yourself, add a second GLP‑1, or turn to unapproved products. The labels leave the dose to your prescriber, and say not to combine these medicines.6,7

  • No doubling up: the Wegovy and Zepbound labels say using them with any other GLP‑1 medicine is not recommended.6,7
  • No unapproved add-ons: compounded versions are not FDA-approved, and the FDA has reports of people hospitalized after dosing errors with compounded semaglutide.16 See our posts on compounded GLP‑1s and “GLP‑1” patches, drops and supplements.
  • Stopping on your own brings weight back: in SURMOUNT-4, everyone first took Zepbound at 10 or 15 mg for 36 weeks. Those then switched to a dummy injection regained 14.0% of their weight over a year; those who stayed on Zepbound lost another 5.5%. Stopping is a decision for you and your prescriber; our stopping guide covers it.14
RisksThe risks, in brief
  • Stomach effects are the most common: on Zepbound 5, 10 or 15 mg, 25 to 29 in 100 had nausea, against 8 in 100 on a dummy injection.7
  • Skin tingling or burning was more common on Wegovy 7.2 mg: 22 in 100, against 6 in 100 on 2.4 mg.6
  • Pancreatitis and gallbladder problems are label warnings for both medicines.6,7
  • Thyroid tumors were seen in rodents; both labels carry a boxed warning.6,7
Full detail in our side-effects guide →
Get help now: call 911 if someone collapses, has a seizure, has trouble breathing or can’t be woken.17 Severe stomach pain that won’t go away, sometimes spreading to the back, is a pancreatitis warning sign on the labels: call your prescriber right away.6,7 Poison Control is 1-800-222-1222.17

Questions people ask

Is it normal to stop losing weight on Zepbound?

Yes. In an analysis of SURMOUNT-1 by mostly Eli Lilly researchers, 88 to 90 in 100 people who lost at least 5% on Zepbound 5, 10 or 15 mg had reached a plateau by week 72.4

How long does a Wegovy plateau last?

In STEP 5, weight on Wegovy 2.4 mg flattened after about week 60 and held at that level to week 104 while people kept taking it.1

Should my dose go up if I plateau?

That is your prescriber’s call. The labels allow Wegovy up to 7.2 mg and Zepbound up to 15 mg, weighing response and side effects.6,7

Will switching from Wegovy to Zepbound break a plateau?

No trial we found has tested that. SURMOUNT-5 compared the two in people started on one or the other, not people switching.15

Do I need to keep taking it if I’m not losing more weight?

In SURMOUNT-4, after 36 weeks on Zepbound 10 or 15 mg, people switched to a dummy injection regained 14.0% of their weight in a year. Those who stayed on Zepbound lost another 5.5%. Whether to continue is a decision for you and your prescriber.14

How we researched this

On October 14, 2026, we read the STEP 1, STEP 5, SURMOUNT-1, SURMOUNT-4 and SURMOUNT-5 trial reports. We also read a 2025 analysis of when plateaus happen on tirzepatide and a 2018 review of why weight loss slows.

We read the current US Wegovy, Zepbound and Saxenda labels and two NIH pages. We added the ADA’s 2026 summary of changes, the 2025 nutrition advisory and one published health-plan policy.

The STEP trials were paid for by Novo Nordisk, and the SURMOUNT trials by Eli Lilly; most authors of the plateau analysis work for Lilly. We give trial averages, not predictions, and we name no pharmacy, clinic or telehealth service.

Before you move on

  • A plateau is the usual pattern: Wegovy flattened after about week 60 in STEP 5.
  • Appetite rising as weight falls explains much of it.
  • The labels let a prescriber review the dose; higher doses bring more side effects.
  • Don’t change doses or add products on your own.
I’m already on itStopping a GLP‑1Doctor questions tool

More from the US blog

USUnited StatesSwitching from one GLP‑1 to another: what the US labels say USUnited StatesWegovy HD 7.2 mg: what the higher dose means USUnited StatesWhat happens when you stop Wegovy or Zepbound?
About GLP Guidebook

The monthly US update

An independent guide to GLP‑1 medicines. We don't sell medicines, take drug-company money or earn clinic commissions. Once a month: FDA approvals and safety notices, label changes, Medicare and Medicaid coverage changes, and published price changes. How we write

Was this post easy to understand?

Sources

  1. Garvey WT, Batterham RL, Bhatta M et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022;28(10):2083–91. Funded by Novo Nordisk. DOI · PMC9556320
  2. Wilding JPH, Batterham RL, Calanna S et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384(11):989–1002. Funded by Novo Nordisk. DOI · PMID 33567185
  3. Jastreboff AM, Aronne LJ, Ahmad NN et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387(3):205–16. Funded by Eli Lilly. DOI · PMID 35658024
  4. Horn DB, Kahan S, Batterham RL et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes 2025;15(3):e12734. Several authors employed by Eli Lilly. DOI · PMID 39800653
  5. Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. Med Clin North Am 2018;102(1):183–97. DOI · PMC5764193
  6. Novo Nordisk. Wegovy (semaglutide) injection and tablets: US prescribing information, revised 06/2026. novo-pi.com
  7. Eli Lilly. Zepbound (tirzepatide) injection: US prescribing information, revised 08/2026. pi.lilly.com
  8. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, part of NIH). Prescription medications to treat overweight and obesity. Last reviewed June 2024. niddk.nih.gov
  9. NIDDK. Factors affecting weight and health. Last reviewed May 2023. niddk.nih.gov
  10. American Diabetes Association Professional Practice Committee. Summary of revisions: Standards of Care in Diabetes—2026 (section 8, recommendations 8.15 and 8.21). Diabetes Care 2026;49(Suppl 1):S6. DOI · PMID 41358896
  11. Mozaffarian D, Agarwal M, Aggarwal M et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society. Am J Clin Nutr 2025;122:344–67. PMC12612741
  12. Novo Nordisk. Saxenda (liraglutide) injection: US prescribing information, revised 02/2026. novo-pi.com
  13. Neighborhood Health Plan of Rhode Island. Weight loss management: Wegovy (semaglutide), Zepbound (tirzepatide). Pharmacy policy, effective 01/2026, reviewed 08/2025 (one example of a published US health-plan policy). nhpri.org
  14. Aronne LJ, Sattar N, Horn DB et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331(1):38–48. Funded by Eli Lilly. DOI · PMID 38078870
  15. Aronne LJ, Horn DB, le Roux CW et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025;393(1):26–36. Funded by Eli Lilly. DOI · PMID 40353578
  16. US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Content current as of 10/01/2026. fda.gov
  17. Poison Control (National Capital Poison Center). Opened October 14, 2026. poison.org

Last checked Oct 14, 2026 · Next review due Oct 14, 2027 · Report an error

How this post was made. Written by the GLP Guidebook team from the sources above. It's general information, not medical or legal advice. Talk to a qualified doctor, nurse practitioner or pharmacist before starting, stopping or changing any medicine. How we write